Funder: National Institutes of Health
Due Dates: August 14, 2025 (New, Renewal, Resubmission, Revision) | January 16, 2026 (New, Renewal, Resubmission, Revision) | August 14, 2026 (New, Renewal, Resubmission, Revision)
Funding Amounts: R61 phase: up to $600,000 direct costs (2 years); R33 phase: no budget cap (up to 3 years); total project period up to 5 years. NIH/NIDA expects to fund up to 6 awards across this and companion NOFOs.
Summary: Supports exploratory, mechanistic clinical research to identify and validate novel non-invasive brain stimulation (NIBS) targets and SUD-relevant responses to NIBS that precede clinical outcomes.
Key Information: Applications must propose basic experimental studies with humans (BESH) that meet the NIH clinical trial definition and basic research criteria; preliminary data are not required; milestones are required for R61-to-R33 transition.